← Eichor
Study identifier: NCT06675344 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

Condition: Systemic Sclerosis (SSc)  ·  Sponsor: Robyn T. Domsic, MD, MPH

PhaseNA
Planned participants160
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifically, we will evaluate if the Apollo Neuro device may improve the two specific symptoms highest ranked by patients as affecting qualify of life (fatigue, Raynaud phenomenon) as co-primary outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Maureen M Laffoon, BS  ·  412-648-7871  ·  laffoonm@pitt.edu

Robyn T Domsic, MD  ·  412-647-6700  ·  rtd4@pitt.edu

Always discuss trial participation with your own doctor first.

Locations (4)

DelRicht Research CenterNew Orleans, Louisiana, United StatesRecruiting
University of MichiganAnn Arbor, Michigan, United StatesRecruiting
University of Pittsburgh and UPMC Scleroderma CenterPittsburgh, Pennsylvania, United StatesRecruiting
Vanderbilt University Medical CenterNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06675344